A second phase IIa trial to investigate RT-002 (DaxibotulinumtoxinA) for the treatment of plantar fasciitis
Phase of Trial: Phase II
Latest Information Update: 07 Jan 2019
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Plantar fasciitis
- Focus Therapeutic Use
- 07 Jan 2019 According to a Revance Therapeutics media release, patient dosing has been initiated in this study.
- 07 Jan 2019 Status changed from planning to recruiting, according to a Revance Therapeutics media release.
- 04 Dec 2018 According to a Revance Therapeutics media release, the company plans to announce first patient dosing before year-end 2018.